Among several candidate molecules identified in the screening, we focused on FNDC3B (fibronectin type III domain containing 3B) because this molecule showed no similarity to any of the molecules previously known to be involved in CF synapse elimination. Here, FNDC3B is linked to cystic fibrosis.